Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun 9:13:867013.
doi: 10.3389/fimmu.2022.867013. eCollection 2022.

The Past, Present, and Future of Non-Viral CAR T Cells

Alex Moretti  1 , Marianna Ponzo  1 , Charles A Nicolette  2 , Irina Y Tcherepanova  2 , Andrea Biondi  1   3   4 , Chiara F Magnani  1   5
Affiliations
Review

The Past, Present, and Future of Non-Viral CAR T Cells

Alex Moretti et al. Front Immunol. .

Abstract

Adoptive transfer of chimeric antigen receptor (CAR) T lymphocytes is a powerful technology that has revolutionized the way we conceive immunotherapy. The impressive clinical results of complete and prolonged response in refractory and relapsed diseases have shifted the landscape of treatment for hematological malignancies, particularly those of lymphoid origin, and opens up new possibilities for the treatment of solid neoplasms. However, the widening use of cell therapy is hampered by the accessibility to viral vectors that are commonly used for T cell transfection. In the era of messenger RNA (mRNA) vaccines and CRISPR/Cas (clustered regularly interspaced short palindromic repeat-CRISPR-associated) precise genome editing, novel and virus-free methods for T cell engineering are emerging as a more versatile, flexible, and sustainable alternative for next-generation CAR T cell manufacturing. Here, we discuss how the use of non-viral vectors can address some of the limitations of the viral methods of gene transfer and allow us to deliver genetic information in a stable, effective and straightforward manner. In particular, we address the main transposon systems such as Sleeping Beauty (SB) and piggyBac (PB), the utilization of mRNA, and innovative approaches of nanotechnology like Lipid-based and Polymer-based DNA nanocarriers and nanovectors. We also describe the most relevant preclinical data that have recently led to the use of non-viral gene therapy in emerging clinical trials, and the related safety and efficacy aspects. We will also provide practical considerations for future trials to enable successful and safe cell therapy with non-viral methods for CAR T cell generation.

Keywords: adoptive cell transfer; cancer therapy; chimeric antigen receptor (CAR T); gene therapy; immunotherapy; mRNA; non-viral vectors; transposons.

PubMed Disclaimer

Conflict of interest statement

Authors CM and AB are inventors on a patent related to non-viral CAR-T cell therapy (European patent application 15801344), filed by the Tettamanti Foundation, and licensed to CoImmune. Authors CN and IT are executive officers of CoImmune. Author AB has received fundings from AIRC 5x1000 2018-21147, PRIN 2017-NAZ-0412, and the Ministero della Salute CAR-T project of the “Rete Oncologica”. The remaining authors declare that the research was conducted in the absence of any commercial or financial conflict of interests.

Figures

Figure 1
Figure 1
Worldwide approval status of CAR T cell drugs.
Figure 2
Figure 2
SB and PB mediated integration.
Figure 3
Figure 3
mRNA vector.
Figure 4
Figure 4
Non-viral CAR T cell generation.
See this image and copyright information in PMC

References

    1. Eshhar Z, Waks T, Gross G, Schindler DG. Specific Activation and Targeting of Cytotoxic Lymphocytes Through Chimeric Single Chains Consisting of Antibody-Binding Domains and the Gamma or Zeta Subunits of the Immunoglobulin and T-Cell Receptors. Proc Natl Acad Sci USA (1993) 90:720–4. doi: 10.1073/pnas.90.2.720 - DOI - PMC - PubMed
    1. Majzner RG, Mackall CL. Clinical Lessons Learned From the First Leg of the CAR T Cell Journey. Nat Med (2019) 25:1341–55. doi: 10.1038/s41591-019-0564-6 - DOI - PubMed
    1. Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in Children and Young Adults With B-Cell Lymphoblastic Leukemia. N Engl J Med (2018) 378:439–48. doi: 10.1056/NEJMoa1709866 - DOI - PMC - PubMed
    1. Gardner RA, Finney O, Annesley C, Brakke H, Summers C, Leger K, et al. Intent-To-Treat Leukemia Remission by CD19 CAR T Cells of Defined Formulation and Dose in Children and Young Adults. Blood (2017) 129:3322–31. doi: 10.1182/blood-2017-02-769208 - DOI - PMC - PubMed
    1. Turtle CJ, Hanafi L-A, Berger C, Gooley TA, Cherian S, Hudecek M, et al. CD19 CAR-T Cells of Defined CD4+:CD8+ Composition in Adult B Cell ALL Patients. J Clin Invest (2016) 126:2123–38. doi: 10.1172/JCI85309 - DOI - PMC - PubMed

Publication types